Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 4,226 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Completed Phase 2 Interventional Results available

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

NCT01389973
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Jacksonville, Florida • Miami, Florida • Naples, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2016 · Synced Nov 10, 2026, 4:10 AM EST
Terminated Phase 3 Interventional Results available

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Nov 10, 2026, 4:10 AM EST
Recruiting Phase 3 Interventional

Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis

NCT07228104
View directory record Official record
Conditions
Idiopathic Subglottic Stenosis
Interventions
Triamcinolone 0.1%, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Infrapatellar Nerve Block for Post-operative Knee Arthroscopy Pain Control

NCT01279447
View directory record Official record
Conditions
Internal Derangement of Knee
Interventions
0.25% Bupivacaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Nov 10, 2026, 4:10 AM EST
Terminated Phase 2 Interventional Results available

A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis

NCT01732211
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
PD 0360324, Normal Saline for injection
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
5
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to an Investigational Dengue Type 2 Vaccine

NCT01073306
View directory record Official record
Conditions
Dengue Virus
Interventions
Investigational Vaccine for Dengue Virus Subtype 2, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847
View directory record Official record
Conditions
Drug Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 3 Interventional Results available

Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

NCT04719832
View directory record Official record
Conditions
Asthma
Interventions
GSK3511294 (Depemokimab), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
30
States / cities
Encinitas, California • Long Beach, California • Pasadena, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 1Phase 2 Interventional Results available

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

NCT03560258
View directory record Official record
Conditions
HIV Infections
Interventions
p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Nov 10, 2026, 4:10 AM EST
Terminated Phase 3 Interventional Results available

A Study of Benralizumab in Patients With Eosinophilic Esophagitis

NCT04543409
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Benralizumab, Matching placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

NCT00906399
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
BIIB017 (peginterferon beta-1a), Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Phoenix, Arizona • Ponte Vedra Beach, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2014 · Synced Nov 10, 2026, 4:10 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 2 Interventional

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

NCT01397578
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Nov 10, 2026, 4:10 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Validating a New Non-invasive Approach to Testing Lidocaine Effectiveness

NCT03680885
View directory record Official record
Conditions
ADHD, Controls
Interventions
Lidocaine gel, Placebo, Injected lidocaine
Drug
Lead sponsor
PhenoSolve, LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

NCT02066415
View directory record Official record
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
Erenumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
34
States / cities
La Jolla, California • Newport Beach, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

NCT02267135
View directory record Official record
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Nov 10, 2026, 4:10 AM EST
Active, not recruiting Not applicable Interventional

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

NCT03455725
View directory record Official record
Conditions
Refractory Angina, Chronic Myocardial Ischemia
Interventions
CardiAMP Cell Therapy System, Sham Treatment
Device · Other
Lead sponsor
BioCardia, Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Gainesville, Florida • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

NCT00794664
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Mipomersen, Placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
9
States / cities
Jupiter, Florida • Winter Park, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Nov 10, 2026, 4:10 AM EST
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging and Dose Frequency of LIPO-102

NCT00918814
View directory record Official record
Conditions
Subcutaneous Adipose Tissue Reduction
Interventions
LIPO-102, Placebo
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Diego, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL for Minimally Invasive Supracervical Hysterectomies

NCT03769714
View directory record Official record
Conditions
Pain
Interventions
Saline Solution for Injection, Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Nov 10, 2026, 4:10 AM EST
Not listed Not applicable Interventional

Comparative Evaluation of A-CP HA Kit, Hyaluronic Acid and Placebo for the Treatment of Knee Osteoarthritis

NCT03201614
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
A-CP HA Kit, ArthroVisc 40, Placebo
Device · Drug
Lead sponsor
Regen Lab SA
Industry
Eligibility
50 Years to 80 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Nov 10, 2026, 4:10 AM EST
Completed Phase 2 Interventional Results available

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

NCT01124006
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Intradiscal rhGDF-5, Water for injection
Drug · Other
Lead sponsor
DePuy Spine
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Phoenix, Arizona • Santa Monica, California • Durango, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Nov 10, 2026, 4:10 AM EST
Active, not recruiting Phase 3 Interventional

The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial

NCT02261415
View directory record Official record
Conditions
Cancer, Tumour, Surgery
Interventions
Tranexamic acid (TXA), Normal saline
Drug
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
1,386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Nov 10, 2026, 4:10 AM EST